Anaemia: Pathophysiology Pharmacological Management And Emerging Therapies

[1]Ms.Divya Jagannath Maind,[2]Miss.Madhuri Shrawane , [3]Mr Dr. D. K.Vir.

[4]Ms. Pooja Pandurang More, [5]Kalyani Ashok Mhaske.

[1],[4],[5](student), [2](Associate Professor (Guide),[3](Principal)

Department Of Pharmaceutical Science and Technology Shree Goraksha College of Pharmacy and Research Center Khamgaon..

1. Abstract:

Anaemia is a global health disorder characterized by a reduction in red blood cell count or hemoglobin concentration, resulting in decreased oxygen-carrying capacity of the blood. It affects approximately one-third of the global population, particularly women, children, and the elderly
(1). The objective of this review is to provide an updated overview of the pathophysiology, etiology, diagnosis, and pharmacological as well as non-pharmacological management of anemia. Various types of anemia, including iron-deficiency, vitamin B12 deficiency, folate deficiency, hemolytic, and aplastic anemia, arise from impaired erythropoiesis, blood loss, or increased red blood cell destruction. Diagnostic evaluation involves complete blood count, peripheral smear, and serum studies for iron, ferritin, and vitamin levels.

2 .Keywords: Anemia, Iron Deficiency, Pharmacological Management, Hemoglobin, Vitamin B12, Gene Therapy

3 . Introduction

Anemia is a blood disorder in which the hemoglobin level or the number of red blood cells becomes lower than normal. As a result, the blood cannot carry enough oxygen from the lungs to body tissues. This lack of oxygen affects normal body functions because oxygen is vital for energy production and cell activity. Anemia is a widespread global healtissua ffecti g people of all ages. The most common type is **iron deficiency anemia**, which often occurs due to poor dietary intake of iron, ongoing blood loss, or increased body requirements during periods like **pregnancy and rapid growth**. Other causes include lack of **vitamin B12 or folate**, long-term illnesses, **genetic conditions**, problems in the **bone marrow**, and disorders that lead to **increased destruction of red blood cells**. It reduces the body's ability to transport oxygen efficient



Figure 1 : Structure of red blood cells and the mechanism of oxygen transport.

4. Objective :

1: To provide a comprehensive overview of anemia

This objective aims to deliver a concise yet detailed understanding of anemia as a globally important blood disorder. It involves defining anemia using standard hemoglobin levels, examining its occurrence across different age groups, and emphasizing its impact on public health—especially among women, children, and the elderly. By evaluating its epidemiologica trends, this objective highlights anemia as not only a medical issue but also a socio-economic concern affecting healthcare systems and overall quality of life.

2. To understand the pathophysiological mechanisms underlying anemia

This objective aims to explain how anemia develops by examining the physiological processes involved in red blood cell production and maintenance. It highlights how impaired erythropoiesis, increased red cell destruction, or blood loss reduces the blood's capacity to carry oxygen. Key components include the role of erythropoietin in stimulating RBC formation, proper iron metabolism, functional bone marrow activity, and the involvement of essential nutrients such as vitamin B12 and folate. Understanding these mechanisms is crucial for accurate diagnosis and effective treatment plannin

5. Classification / Types of Anemia :-

Anemia is a diverse condition, and proper classification helps understand its causes, diagnosis, and treatment. It can be classified based on
etiology (cause) or **morphology (red blood cell characteristics).**

A. Etiological Classification

1. **Iron-Deficiency Anemia (IDA):**

Occurs due to lack of iron needed for hemoglobin production. Causes include poor diet, chronic blood loss (e.g., heavy menstruation or gastrointestinal bleeding), or poor absorption. Common symptoms are fatigue, pale skin, brittle nails, and sometimes pica.

2. **Megaloblastic Anemia:**

Caused by vitamin B_{12} or folate deficiency, leading to the formation of large, immature red blood cells (megaloblasts). Symptoms include weakness, glossitis, and neurological issues such as tingling or memory problems.

3. **Hemolytic Anemia:**

Results from the early destruction of red blood cells. It may be inherited (e.g., sickle cell disease) or acquired (e.g., autoimmune causes, drugs, infection). Presents with jaundice, dark urine, pallor, and splenomegaly.

4. **Aplastic Anemia:**

Due to failure of bone marrow to produce blood cells (pancytopenia). Can result from toxins, radiation, drugs, viral infections, or autoimmune activity. Symptoms include fatigue, frequent infections, and easy bleeding.

5. **Anemia of Chronic Disease (ACD):**

Associated with long-term illnesses such as chronic infections or autoimmune disea.

B. Morphological Classification

1. **Microcytic Anemia (Low MCV):**

Seen in iron deficiency anemia and thalassemia. Red blood cells are small and pale.

2. **Normocytic Anemia (Normal MCV):**

Common in acute blood loss and chronic disease. RBCs are normal in size but reduced in number.

3. **Macrocytic Anemia (High MCV):**

Occurs due to vitamin B_{12} or folate deficiency. RBCs are large from impaired DNA synthesis.

4. **Bottom of Form**

6. Etiology / Causes of Anemia

Anemia can develop due to many different factors that affect how red blood cells (RBCs) are made, how long they survive, or how much is lost from the body. Major causes include:

1. **Nutritional deficiencies**

Lack of iron, vitamin B12, or folate is a common cause.

- **Iron deficiency** affects hemoglobin formation → small, pale RBCs.
- **Vitamin B12/Folate deficiency** affects cell division → large, immature RBCs (megaloblasts).

Poor diet, absorption issues, pregnancy, and strict eating habits can lead to these deficiencies.

2. **Chronic diseases**

Long-term illnesses like kidney disease, cancer, infections, and autoimmune disorders reduce RBC production and affect iron use. In kidney disease, low erythropoietin levels reduce RBC formation.

3. **Genetic disorders**

- **Thalassemia** – defective hemoglobin production.
- **Sickle cell anemia** – abnormal hemoglobin causes RBCs to become sickle-shaped and break easily. These disorders usually start early and need lifelong care.

4. **Blood loss**

- **Acute loss** (e.g., injury or surgery) reduces blood quickly.
- **Chronic loss** (e.g., ulcers, parasitic infection, or heavy periods) gradually lowers iron stores and leads to anemia.

5. **Drugs and toxins**

- Chemotherapy damages bone marrow → less RBC production.
- Long-term NSAID use may cause bleeding.
- Heavy metals like lead interfere with hemoglobin formation and destroy RBCs.

7 . Pathophysiology (How anemia develops)

Anemia happens when the body cannot maintain enough healthy red blood cells to carry oxygen. There are **three main mechanisms**:

1. **Decreased RBC production**

Due to nutritional deficiency, bone marrow disease, or low erythropoietin.

2. **Increased RBC destruction (hemolysis)**

Occurs in genetic disorders (like sickle cell anemia) or exposure to toxins.

3. **Blood loss**

Through injury, surgery, menstr



Figure 2: Pathophysiology of anemia showing major mechanisms: impaired production, destruction, and blood loss.

8. Clinical Features / Symptoms of Anemia

The symptoms of anemia vary depending on its cause, severity, and how quickly it develops. Reduced hemoglobin levels lead to decreased oxygen supply to tissues, resulting in general and type-specific symptoms. Mild anemia may show no signs, while moderate to severe anemia causes noticeable changes.

1. General Symptoms

Common symptoms seen in most types of anemia include:

- **Fatigue and weakness** – due to low oxygen reaching muscles.
- **Pale skin and mucous membranes** – from reduced hemoglobin.
- **Shortness of breath (dyspnea)** – especially during physical activity.
- **Palpitations or fast heartbeat (tachycardia)** – as the heart works harder.

9. Pharmacological Management of Anemia

Treatment of anemia depends on its underlying cause. The main goal is to raise hemoglobin levels, replace missing nutrients, and improve oxygen supply to the body. Therapy is selected based on the type of anemia, severity, and patient needs.

1. Iron-Deficiency Anemia

- **Drugs:** Ferrous sulfate, ferrous fumarate, ferrous gluconate
- **How it works:** Supplies elemental iron needed to make hemoglobin.
- **Dose:** About 200 mg elemental iron, taken 1–3 times daily.
- **Side effects:** Constipation, nausea, stomach pain, dark stools.
- **Route:** Oral is preferred; IV iron is used if oral is ineffective or not tolerated.

2. Vitamin B12 Deficiency Anemia

- **Drugs:** Cyanocobalamin, hydroxocobalamin
- **How it works:** Replaces vitamin B12 to support red blood cell production and nerve function.
- **Dose:** 1000 µg intramuscularly weekly until corrected, then maintenance.
- **Route:** Usually IM; high oral doses may be used if absorption is normal.

3 . Folate Deficiency Anemia

- **Drug:** Folic acid
- **How it works:** Provides folate required for DNA synthesis and red blood cell maturation.



Figure 3 : Pharmacological Management Pathway of Anemia 10 .

Non-Pharmacological Management

Along with medicines, non-pharmacological measures are important for preventing and managing anemia. These strategies help improve red blood cell (RBC) production, increase nutrient absorption, and correct lifestyle habits that may worsen anemia.

1. Dietary Modifications

Diet plays a major role in improving anemia. Eating the right foods helps restore iron levels and supports hemoglobin formati

- **Include Iron-Rich Foods:**

Eat foods such as red meat, chicken, fish, spinach, beans, lentils, nuts, seeds, and iron-fortified cereals. Iron from animal sources (heme iron) is absorbed better than iron from plant sources (non-heme iron).

- **Add Vitamin C Foods:**

Foods like oranges, lemons, tomatoes, amla, and bell peppers help increase the absorption of non-heme iron from plant-based foods.

- **Follow a Balanced Diet:**

Ensure sufficient intake of:

- **Vitamin B12:** Found in milk, eggs, fish, and meat.
- **Folate (Vitamin B9):** Found in green leafy vegetables, legumes, fruits, and fortified grains. These nutrients are essential for proper RBC formation and help prevent megaloblastic anemia.

11 .Conclusion

Anemia remains a widespread health issue affecting people of all ages worldwide. Because it can arise from multiple causes, understanding its mechanisms is important for proper diagnosis and treatment. Early detection through tests and timely management using medicines and nutritional support can help prevent serious complications.

Emerging approaches like gene therapy and nanotechnology-based treatments offer hope for more effective and long-lasting management. To reduce the impact of anemia and improve health outcomes, coordinated global efforts and awareness are essential.

12 . References

1. **WHO. (2023). Global prevalence of anemia in 2023. World Health Organization. Retrieved from**

2. **Guyton, A.C., & Hall, J.E. (2022). Textbook of Medical Physiology. Elsevier.**

3. **Kassebaum, N.J. (2023). The global burden of anemia. Blood Journal.**

4. **WHO. (2022). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Retrieved from**

5. **Short, M.W., Domagalski, J.E. (2023). Iron deficiency anemia: Evaluation and management. American Family Physician. 11.References 11.References**

1. **WHO. (2023). Global prevalence of anemia in 2023. World Health Organization. Retrieved from**

2. **Guyton, A.C., & Hall, J.E. (2022). Textbook of Medical Physiology. Elsevier.**

3. Kassebaum, N.J. (2023). The global burden of anemia. Blood Journal.

4. WHO. (2022). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Retrieved from

5. Short, M.W., Domagalski, J.E. (2023). Iron deficiency anemia: Evaluation and management. American Family Physician. Retrieved from

6. Green, R. (2022). Megaloblastic anemias: B12 and folate deficiency. NEJM, 386(2), 160–172.

7. Young, N.S. (2023). Hemolytic anemias and bone marrow failure. Hematology Reviews, 15(3), 245–259.

8. Miller, J.L. (2022). Iron deficiency anemia: A common and curable disease. Cold Spring Harb Perspect Med, 12(4).

9. Weiss, G., Goodnough, L.T. (2023). Anemia of chronic disease. NEJM, 387(3), 200–210.

10. Weatherall, D.J. (2023). Thalassemia and related disorders. Blood Rev, 45, 100–115.

11. Cappellini, M.D., et al. (2022). Iron deficiency across chronic diseases. Haematologica, 107(7), 1502–1511.

12. Killip, S., Bennett, J.M. (2023). Iron deficiency anemia: Pathophysiology and management. Am Fam Physician, 107(2), 124–133.

13. Schrier, S.L. (2023). Pathophysiology of hemolytic anemia. UpToDate. Retrieved from

14. O'Leary, F., & Samman, S. (2022). Vitamin B12 in health and disease. Nutrients, 14(3), 762–770.

15. Camaschella, C. (2022). Iron deficiency anemia. NEJM, 386(3), 349–360.

16. Stabler, S.P. (2023). Vitamin B12 deficiency and related disorders. Med Clin North Am, 107(4), 741–755.

17. Lynch, S.R. (2022). Diagnostic approaches in anemia. Clin Chem Lab Med, 60(9), 1342–1350.

18. WHO. (2023). Diagnostic thresholds for iron deficiency anemia. Retrieved from

19. McLean, E. et al. (2023). Therapeutic iron formulations and bioavailability. Nutrients, 15(3), 512–526.

20. O'Leary, F., Samman, S. (2022). Vitamin B12 supplementation in anemia. Nutrients, 14(3), 771–779.

21. Bailey, L.B. (2023). Folate and human health. Adv Nutr, 14(1), 142–154.

22. Fishbane, S., & Spinowitz, B.S. (2022). Erythropoiesis-stimulating agents in CKD. Am J Kidney Dis, 79(5), 725–733.

23. Zimmermann, M.B. (2022). Nutritional iron deficiency. Lancet, 400(10366), 183–196.

24. Anselmo, A.C., & Mitragotri, S. (2022). Nanomedicine approaches to iron supplementation. J

Control Release, 352, 572–583.

25. **Cavazzana, M. (2023). Gene therapy for thalassemia and sickle cell anemia. Nature Medicine, 29, 458–472.**

26. **Chen, N., et al. (2023). HIF-prolyl hydroxylase inhibitors in anemia management. NEJM, 388(7), 615–625.1.**

WHO. (2023). Global prevalence of anemia in 2023. World Health Organization. Retrieved from